Discovery of AB680: A Potent and Selective Inhibitor of CD73
Author:
Affiliation:
1. Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States
2. Institute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, D-04103 Leipzig, Germany
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00525
Reference43 articles.
1. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
2. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
3. The future of immune checkpoint therapy
4. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
5. Tumour-intrinsic resistance to immune checkpoint blockade
Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Breakthrough of solid tumor treatment: CAR-NK immunotherapy;Cell Death Discovery;2024-01-20
2. A comprehensive review of discovery and development of drugs discovered from 2020–2022;Saudi Pharmaceutical Journal;2024-01
3. Small molecular CD73 inhibitors: Recent progress and future perspectives;European Journal of Medicinal Chemistry;2024-01
4. Adenosine in cancer immunotherapy: Taking off on a new plane;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-11
5. The small molecule CBR-5884 inhibits theCandida albicansphosphatidylserine synthase;2023-11-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3